Immunic Inc. (IMUX)
| Bid | 0.94 |
| Market Cap | 96.51M |
| Revenue (ttm) | 114K |
| Net Income (ttm) | -101.84M |
| EPS (ttm) | -1.02 |
| PE Ratio (ttm) | -0.96 |
| Forward PE | -2.29 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 1 |
| Volume | 1,660,369 |
| Avg. Volume (20D) | 1,268,933 |
| Open | 0.95 |
| Previous Close | 0.96 |
| Day's Range | 0.93 - 0.99 |
| 52-Week Range | 0.56 - 1.73 |
| Beta | 1.56 |
| Ex-Dividend Date | n/a |
About IMUX
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for IMUX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts
5 days ago · proactiveinvestors.com
Immunic is aiming for a big breakthrough in the treatment of multiple sclerosisAn unheralded New York–listed biotech is chasing one of neurology's biggest goals: a pill that not only tamps down the inflammatory flares of multiple sclerosis but also directly protects the brain fr...
1 week ago · proactiveinvestors.com
Immunic highlights multiple sclerosis drug findings at key neurology gatheringImmunic Inc (NASDAQ:IMUX) has presented clinical trial data suggesting its oral therapy, vidofludimus calcium, could help slow disability in patients with progressive multiple sclerosis, a form of the...
3 weeks ago · proactiveinvestors.com
Immunic secures US patent protection for vidofludimus calcium in dose strengths in progressive MSImmunic Inc (NASDAQ:IMUX) announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) covering dose strengths of its lead asset, vidofludimus calciu...
1 month ago · proactiveinvestors.com
Immunic reports promising Phase 2 data for lead drug candidate in progressive MS - ICYMIImmunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive about the company's second quarter highlights, with a particular focus on clinical progress in its multiple sclerosis (MS) programs. ...
1 month ago · proactiveinvestors.com
Immunic advances MS drug program with Phase 3 trials fully enrolledImmunic Inc (NASDAQ:IMUX) said on Thursday it has fully enrolled its twin Phase 3 ENSURE trials for vidofludimus calcium, positioning the company for a major data readout by end-2026 in relapsing mult...